Isis Accused of Hiding Cholesterol Drug's Safety Risks

Published January 3, 2013

Isis Accused Of Hiding Cholesterol Drug's Safety Risks

Filed under: drug treatment programs in california

… 2013, 3:34 PM ET) — A putative class action launched Friday in California federal court alleges Isis Pharmaceuticals Inc. misled investors over the safety and effectiveness of cholesterol disorder treatment Kynamro, which U.S. Food and Drug …
Read more on Law360 (subscription)

ThriveRx Receives Limited Distribution Rights to Gattex (Teduglutide [rDNA …

Filed under: drug treatment programs in california

Gattex was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2012 as a treatment for adults with SBS who are dependent on parenteral support. Gattex is NPS's proprietary analog of a naturally occurring peptide involved in the …
Read more on PharmaLive (press release) (subscription)